Cargando…
COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges
Lung cancer, considered one of the most common causes of cancer deaths worldwide, is a complex disease with its own challenges. The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compounded these challenges and forced the medical...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515530/ https://www.ncbi.nlm.nih.gov/pubmed/36154328 http://dx.doi.org/10.1177/03000605221125047 |
_version_ | 1784798503501824000 |
---|---|
author | Moubarak, Simon Merheb, Diala Basbous, Lynn Chamseddine, Nathalie Bou Zerdan, Maroun Assi, Hazem I |
author_facet | Moubarak, Simon Merheb, Diala Basbous, Lynn Chamseddine, Nathalie Bou Zerdan, Maroun Assi, Hazem I |
author_sort | Moubarak, Simon |
collection | PubMed |
description | Lung cancer, considered one of the most common causes of cancer deaths worldwide, is a complex disease with its own challenges. The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compounded these challenges and forced the medical healthcare system to alter its approach to lung cancer. This narrative review aims to identify the effect of the COVID-19 pandemic on lung cancer screening, diagnosis and management. During this public health crisis, various medical societies have worked on developing guidelines to protect patients with lung cancer from the deleterious effects of SARS-CoV-2 infection, as well as from the complications imposed by treatment delays. The different therapeutic approaches, such as surgery, radiation oncology and immune checkpoint inhibitor therapy, along with the latest international recommendations, will be discussed. Protecting patients with lung cancer from COVID-19 complications, while avoiding barriers in treatment delays, has brought unique challenges to healthcare facilities. Prompt modifications to guidelines, and constant evaluation of their efficacy, are thus needed. |
format | Online Article Text |
id | pubmed-9515530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-95155302022-09-29 COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges Moubarak, Simon Merheb, Diala Basbous, Lynn Chamseddine, Nathalie Bou Zerdan, Maroun Assi, Hazem I J Int Med Res Review Lung cancer, considered one of the most common causes of cancer deaths worldwide, is a complex disease with its own challenges. The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compounded these challenges and forced the medical healthcare system to alter its approach to lung cancer. This narrative review aims to identify the effect of the COVID-19 pandemic on lung cancer screening, diagnosis and management. During this public health crisis, various medical societies have worked on developing guidelines to protect patients with lung cancer from the deleterious effects of SARS-CoV-2 infection, as well as from the complications imposed by treatment delays. The different therapeutic approaches, such as surgery, radiation oncology and immune checkpoint inhibitor therapy, along with the latest international recommendations, will be discussed. Protecting patients with lung cancer from COVID-19 complications, while avoiding barriers in treatment delays, has brought unique challenges to healthcare facilities. Prompt modifications to guidelines, and constant evaluation of their efficacy, are thus needed. SAGE Publications 2022-09-25 /pmc/articles/PMC9515530/ /pubmed/36154328 http://dx.doi.org/10.1177/03000605221125047 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Moubarak, Simon Merheb, Diala Basbous, Lynn Chamseddine, Nathalie Bou Zerdan, Maroun Assi, Hazem I COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges |
title | COVID-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
title_full | COVID-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
title_fullStr | COVID-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
title_full_unstemmed | COVID-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
title_short | COVID-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
title_sort | covid-19 and lung cancer: update on the latest screening, diagnosis,
management and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515530/ https://www.ncbi.nlm.nih.gov/pubmed/36154328 http://dx.doi.org/10.1177/03000605221125047 |
work_keys_str_mv | AT moubaraksimon covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges AT merhebdiala covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges AT basbouslynn covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges AT chamseddinenathalie covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges AT bouzerdanmaroun covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges AT assihazemi covid19andlungcancerupdateonthelatestscreeningdiagnosismanagementandchallenges |